Detection of serum soluble B7-H4 in patients with non-metastatic clear cell renal cell carcinoma.

<p>The concentration of the soluble B7-H4 in the HDs and the patients diagnosed with renal cell carcinoma. Sera from 108 renal cancer patients and 108 HDs were diluted 1:10 in PBS and tested by ELISA as described in <a href="http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000166#s2" target="_blank">Materials and Methods</a>. The data were analyzed using the Mann-Whitney U test followed by multiple regression analysis (<i>p</i><0.005).</p

Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma - Fig 3

<p>Progression-free survival (A) and overall survival (B) of non-metastatic clear cell renal cell carcinoma patients with and without serum soluble B7-H4.</p

Patient characteristics.

<p>Patient characteristics.</p

Univariate and multivariate analyses of risk factors predicting overall survival in patients with renal cancer.

<p>Univariate and multivariate analyses of risk factors predicting overall survival in patients with renal cancer.</p

Univariate and multivariate analyses of risk factors predicting progression free survival in patients with renal cancer.

<p>Univariate and multivariate analyses of risk factors predicting progression free survival in patients with renal cancer.</p

The association between serum soluble B7-H4 and peripheral blood neutrophils.

<p><b>A:</b> The data were analyzed using the Mann-Whitney U test followed by multiple regression analysis (<i>p</i><0.005). <b>B:</b> The data summarize the findings of 68 RA patients and were analyzed using Spearman's rank test. y = 0.07x−19.6, R² = 0.428, <i>p</i><0.001.</p